Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by BidaskClub

Share on StockTwits

BidaskClub cut shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong-buy rating to a buy rating in a report published on Saturday, BidAskClub reports.

Other analysts have also recently issued reports about the company. ValuEngine cut Aurinia Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, December 5th. Bloom Burton reiterated a buy rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd. HC Wainwright boosted their price target on Aurinia Pharmaceuticals from $25.00 to $32.00 and gave the stock a buy rating in a research report on Monday, December 16th. Jefferies Financial Group began coverage on Aurinia Pharmaceuticals in a research report on Friday, January 10th. They set a buy rating and a $27.00 price target for the company. Finally, Cantor Fitzgerald boosted their price target on Aurinia Pharmaceuticals from $24.00 to $30.00 in a research report on Thursday, December 5th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $20.41.

Shares of AUPH stock opened at $19.91 on Friday. The stock has a 50 day moving average of $17.34 and a 200 day moving average of $8.62. The stock has a market cap of $2.16 billion, a P/E ratio of -26.20 and a beta of 1.68. Aurinia Pharmaceuticals has a twelve month low of $3.52 and a twelve month high of $21.93.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. Research analysts anticipate that Aurinia Pharmaceuticals will post -0.73 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its stake in Aurinia Pharmaceuticals by 630.1% during the third quarter. Tower Research Capital LLC TRC now owns 8,382 shares of the biotechnology company’s stock worth $45,000 after buying an additional 7,234 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in Aurinia Pharmaceuticals by 42.9% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 10,000 shares of the biotechnology company’s stock worth $53,000 after buying an additional 3,000 shares during the last quarter. Toronto Dominion Bank boosted its stake in Aurinia Pharmaceuticals by 26.3% during the second quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock worth $81,000 after buying an additional 2,575 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new position in Aurinia Pharmaceuticals during the second quarter worth $88,000. Finally, A.R.T. Advisors LLC boosted its stake in Aurinia Pharmaceuticals by 44.9% during the second quarter. A.R.T. Advisors LLC now owns 18,395 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,700 shares during the last quarter. 28.23% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: How Investors Can Profit from Options Trading

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.